Arch Therapeutics, Inc. (OTCMKTS:ARTH – Get Free Report) saw a large increase in short interest in the month of July. As of July 31st, there was short interest totalling 2,500 shares, an increase of 13.6% from the July 15th total of 2,200 shares. Based on an average trading volume of 1,400 shares, the days-to-cover ratio is presently 1.8 days.
Arch Therapeutics Price Performance
ARTH stock opened at $1.55 on Monday. Arch Therapeutics has a 52-week low of $1.10 and a 52-week high of $10.80. The company’s 50-day simple moving average is $2.58 and its 200-day simple moving average is $3.19.
Arch Therapeutics (OTCMKTS:ARTH – Get Free Report) last posted its earnings results on Tuesday, May 23rd. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter. The business had revenue of $0.02 million for the quarter. On average, sell-side analysts forecast that Arch Therapeutics will post -0.03 EPS for the current year.
Arch Therapeutics Company Profile
Arch Therapeutics, Inc, together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease.
See Also
- Five stocks we like better than Arch Therapeutics
- How to Buy Bitcoin Stock: 3 Easy Ways to Do It
- MarketBeat Week in Review – 8/7 – 8/11
- Why Invest in 5G? How to Invest in 5G Stocks
- 3 Retailers To Watch Closely Next Week
- How to Invest in Grocery Stores
- Investing in Coffee: 3 Great Strategies to Consider
Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
